←Back to list

Iambic

Developer of therapeutic discovery quantum molecular simulation engine designed to accelerate molecular discovery.
Developer of therapeutic discovery quantum molecular simulation engine designed to accelerate molecular discovery.
Drug Discovery 📍 San Diego, CA Founded 2019
Current Valuation
$648M
as of 2026-Q2
PRIVATE

QL Price

$485.87M
-25% vs last round
QuantLogix's current estimate for Iambic, published 2026-09-27 — below the last disclosed round of $648M (2026-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round $648M 2026-Q2 weight 0.84
Secondary market print $248.18M 2026-06-27 weight 0.58
How this price has held up
No round has priced for Iambic since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
How to actually get exposure to Iambic →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Iambic, 2026-09-27 (b8015519490c9e53). The id pins this exact claim, so a citation stays checkable after the price moves. Model estimate for research — not a quote, target price, or investment advice.

IPO Outlookprivate

Is Iambic going public?
No. Iambic is private and has not filed to go public. There is no S-1 on file.
What is Iambic's valuation in 2026?
Iambic is valued at $648M as of 2026-Q2, set by its Series B ($27.77M, Apr 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Iambic filed an S-1?
No public S-1 is on file for Iambic.
How much has Iambic raised?
Iambic has raised $354.77M in total, most recently a Series B of $27.77M in Apr 2026.
Is Iambic publicly traded — can you buy Iambic stock?
No. Iambic is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Iambic on its Pre-IPO Access Desk.
How to actually get exposure to Iambic →
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.

Company Profile

Founded
2019
HQ
San Diego, CA
Employees
153
Total Raised
$354.77M
Last Round
Series B — $27.77M (Apr 2026)
IPO Status
private

On the IPO Calendar

Upcoming listing · IAM · Nasdaq
Expected
09/21/2026 est.
Size
$100M
IPO calendar → · preview IAM → · Run DD →
Exchange calendar terms from licensed market-data feeds. Expected dates marked est. are news-derived, not exchange-confirmed. Educational only, not a listing prediction.

Fundraising Status

Series B · $27.77M · 5 mo ago
privateTotal raised $354.77M

Secondary Market

Implied price / share
$1.25
Last round price / share
$3.26
vs last round
-61.7%
Open interest
3
Last round price vs secondary price
Last round vs current secondary price per share$3.26Last round$1.25Current
Secondary price return by period
Secondary market period returns3-month+25.0%6-month+25.0%1-year+25.0%All-time+25.0%
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series B$27.77MApr 2026—$648M

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 1
most advanced registered study
Focus areas
HER2 Mutation-Related Tumors
HER2 · HER2-positive Breast Cancer
Latest trial start
2024-03-25
Name-verified against lead sponsor "Iambic Therapeutics, Inc" on ClinicalTrials.gov as of 2026-09-27. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
▲ Hiring uptrend
+37% vs 2026-08
Open roles
26
via ashby
Product-build share
62%
engineering, research, product, design
Trajectory
expanding
product-led hiring — 62% of open roles build product; the rest are go-to-market and G&A.
No tracked executive churn; open roles trending up.
Open roles by month
Open roles by month19Aug '2626Sep '26
Open roles by function
Open roles by functionResearch11Other5Clinical & Science4Ops & People2Legal & Policy2Finance & Strategy1Engineering1
■ product-building   ■ go-to-market / G&A
Associate Medical Director/Medical DirectorSr Associate Scientist I or II, Medicinal Chemistry Principal Scientist, Medicinal Chemistry Research Scientist II/Senior, Discovery Machine LearningPrincipal Medical WriterMachine Learning Scientist – Clinical Prediction
Counted from Iambic's live job board as of 2026-09-16; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Artificial IntelligenceMachine LearningSoftwareTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.